TSNDF (TerrAscend) Receivables Turnover: 4.49 (As of Mar. 2026)


TSNDF TerrAscend Corp TSNDF
32 GF Score
Price $0.63
GF Value $0.99
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is TerrAscend Receivables Turnover?

TerrAscend TSNDF +1.61% 32 Receivables Turnover is 4.49 as of Mar. 2026. GuruFocus rates TSNDF with a GF Score™ of 32/100 and a GF Value™ of $0.99 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 944 Drug Manufacturers companies, TerrAscend ranks better than 93.33% on this metric.

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. TerrAscend's Revenue for the three months ended in Mar. 2026 was $65.5 Mil. TerrAscend's average Accounts Receivable for the three months ended in Mar. 2026 was $14.6 Mil. Hence, TerrAscend's Receivables Turnover for the three months ended in Mar. 2026 was 4.49.


TerrAscend  (OTCPK:TSNDF) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.


TerrAscend Receivables Turnover Related Terms


TerrAscend Receivables Turnover Historical Data

* Premium members only.

The historical data trend for TerrAscend's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TerrAscend Receivables Turnover Chart

TerrAscend Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.29 18.64 11.60 11.38 15.40

TerrAscend Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.50 3.47 3.72 4.31 4.49

TSNDF vs ZTS, UTHR: Receivables Turnover Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, TerrAscend's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TerrAscend Receivables Turnover vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TerrAscend's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where TerrAscend's Receivables Turnover falls into.


TSNDF
32GF Score
TerrAscend Corp TSNDF
Receivables Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TerrAscend Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

TerrAscend's Receivables Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Receivables Turnover (A: Dec. 2025 )
=Revenue / Average Accounts Receivable
=Revenue (A: Dec. 2025 ) / ((Accounts Receivable (A: Dec. 2024 ) + Accounts Receivable (A: Dec. 2025 )) / count )
=260.558 / ((18.691 + 15.143) / 2 )
=260.558 / 16.917
=15.40

TerrAscend's Receivables Turnover for the quarter that ended in Mar. 2026 is calculated as

Receivables Turnover (Q: Mar. 2026 )
=Revenue / Average Accounts Receivable
=Revenue (Q: Mar. 2026 ) / ((Accounts Receivable (Q: Dec. 2025 ) + Accounts Receivable (Q: Mar. 2026 )) / count )
=65.539 / ((15.143 + 14.024) / 2 )
=65.539 / 14.5835
=4.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Receivables Turnover →
What does a Receivables Turnover of 4.49 mean?
TerrAscend (TSNDF) has a Receivables Turnover of 4.49 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on TerrAscend and its competitors. According to the industry distribution chart, TerrAscend ranks #63 out of 944 companies in the Drug Manufacturers industry, placing it in the top 6.7%.
Is TerrAscend's Receivables Turnover too high?
TerrAscend's current Receivables Turnover is 4.49. The Drug Manufacturers industry median Receivables Turnover is 5.07. TerrAscend's value of 4.49 is 11.4% below this industry median. Based on the distribution chart, TerrAscend ranks #63 out of 944 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TerrAscend has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TerrAscend's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, TerrAscend ranks #63 out of 944 companies for Receivables Turnover. This places TerrAscend in the top 7% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. TerrAscend's value of 4.49 is 11.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TerrAscend's current Receivables Turnover of 4.49 is 11.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on TerrAscend and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TerrAscend's current Receivables Turnover is 4.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TerrAscend stock overvalued right now?
Based on GuruFocus' analysis, TerrAscend (TSNDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.99, compared to a current price of $0.63 — trading 36.4% below its estimated fair value. The current Receivables Turnover is 4.49 and 11.4% below the Drug Manufacturers industry median of 5.07. TerrAscend's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For TerrAscend (TSNDF), the current Receivables Turnover is 4.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TerrAscend (TSNDF) Overvalued in 2026?

Based on GuruFocus' analysis, TerrAscend stock appears to be undervalued. The current stock price of $0.63 is trading 36.4% below its estimated GF Value™ of $0.99. GuruFocus considers TerrAscend to be Possible Value Trap.

Key valuation signals for TSNDF:

  • Receivables Turnover: 4.49
  • GF Value™: $0.99 vs. price of $0.63 (36.4% below fair value)
  • GF Score™: 32/100 with 5 warning signs
  • Industry Position: 11.4% below the Drug Manufacturers median (#63 of 944)

No single metric tells the full story. See the TSNDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TerrAscend Business Description

Other Exchanges TED:GermanyTSND:Canada
Address 77 City Centre Drive, Suite 501, East Tower, Mississauga, ON, CAN, L5B 1M5
TerrAscend Corp is a company focused on creating and delivering cannabis products and services that meet the evolving needs of its patients. It also provides education and support programs to physicians and patients through healthcare professionals. In addition, the firm operates in California, Maryland, New Jersey, and Pennsylvania, with retail operations in Ohio and Canada. It operates The Apothecarium and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. The firm has one operating segment, being the cultivation, production, and sale of cannabis products, with subsidiaries located in Canada and the United States. The company generates key revenue from the United States.
32GF Score

Get the complete analysis for TSNDF

Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.63
Price
$0.99
GF Value